Calypte und die Zeit nach AIDS2004 in Bangkok

etwas kommen. Sicher schon heute denke ich. Wer spielt mit?  

 

 

 

 

 

 

 

 

weggeschlossen.
Selten so einen Typen mit Schräglage gesehen, haha.
Greetz  

mich gar nicht blöde anmachen.
Da müßen schon Leute mit Interlekt kommen und nicht so ein
geistiges Ersatzteillager wie Du ;-).
Bis später
Greetz  

 

Hab im Moment keine, für einen Zock sind die jedoch bald wieder gut ;-).
Gretz  

die Aktie hat seit meinen Ausstieg über 30% abgegeben und liegt in USA heute auch schon wieder fast 14% im minus. Hast Du Deine Papiere immer noch?  

 

Aufräge werden gemeldet und die werden kommen ob diese Woche oder im laufe des Jahres
was ist das Problem ?
Konservative Geschäftspolitik nennt man das !.
Also Kopf hoch  und durch.
Lucky  

als ob die wieder auf alte Tiefststände fallen. Bisher wurde auch nix zu Aufträgen gemeldet. Das die kommen werden, da ist ja wohl eher der Wunsch der Vater des Gedanken.
Bei dem Kursverlauf gestern (fallender Kurs bei extrem hohem Volumen) wäre ich da nicht mehr so optimistisch.

Hoffentlich heisst es da nicht später: Also Kopf hoch und durch bis auf 0,12 $...


Grüße, ZN  

- R. Gale is interim Chief Executive Officer.
- Dr. George intends to continue with the company in an advisory role to assist in the transition to a new chief executive Officer
- R. Gwin is new Chief Financial Officer
- M. Brounstein is Executive Vice President
- Dick Van Maanen has resigned, he continue to work with the company in an advisory capacity
 

Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy

 

 

                                 UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION

                            Washington, D.C. 20549

                                   FORM 8-K

            Current Report Pursuant to Section 13 or 15(d) of the
                       Securities Exchange Act of 1934

      Date of Report (Date of earliest event reported) September 1, 2005


                        Calypte Biomedical Corporation
                        ------------------------------
              (Exact name of Company as specified in its charter)


         Delaware                      000-20985                 06-1226727
         --------                      ---------                 ----------
(State or Other Jurisdiction          (Commission             (I.R.S. Employer
    of Incorporation)                 File Number)             Identification)


            5 Centerpointe Drive, Suite 400, Lake Oswego, OR 97035
            --------------------------------------------------
              (Address of principal executive offices) (Zip Code)


      Registrant's telephone number, including area code: (971) 204-0282


              5000 Hopyard Road, Suite 480, Pleasanton, CA 94568
              --------------------------------------------------
         (Former name or former address, if changed since last report)

|_|   Written communication pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 40.13e-4(c))







Item 1.01      Entry into a Material Definitive Contract.

Effective on September 1, 2005, Calypte Biomedical Corporation ("the Company")
entered into an agreement (the "Agreement") with Marr Technologies Asia Limited
("Marr"), a Seychelles company, to define the respective rights, duties and
obligations of the parties in connection with the ownership and operation of
Beijing Calypte Biomedical Technology Ltd. ("Beijing Calypte"), a joint venture
entity created in the Peoples' Republic of China ("China") to manufacture,
market, distribute and sell certain of the Company's current and future products
in China. Marr is an affiliate of Marr Technologies BV, a Netherlands company,
which currently owns approximately 27% of the Company's outstanding common
stock.

The Agreement authorizes a five-member Board of Directors which is responsible
to manage the business, property and affairs of Beijing Calypte in accordance
with the provisions of the Agreement, Beijing Calypte's Amended and Restated
Articles of Association and all applicable laws. The Board is composed of three
directors designated and appointed by Calypte, each for a four year term, and
two directors designated and appointed by Marr, each for a four year term. Each
Director shall cast one vote on each resolution to be voted upon. The Agreement
further specifies certain major decisions, such as incurring indebtedness,
merging Beijing Calypte with another entity, acquiring another entity or
dissolving Beijing Calypte, among others, which require unanimous vote by the
Board of Directors.

The Agreement provides, with only limited exceptions, that neither Marr nor the
Company has the right to transfer its interest in Beijing Calypte to any other
entity. The Agreement will remain effective until it is terminated upon the
mutual agreement of Marr and the Company or upon a resolution of the Board of
Directors of Beijing Calypte or an order by a court of competent jurisdiction
for the winding down of Beijing Calypte's business affairs.




                                  SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date: Lake Oswego, Oregon
     September 8, 2005

                                  Calypte Biomedical Corporation


                                  By: /s/  Richard D. Brounstein
                                      -----------------------------------------
                                      Richard D. Brounstein
                                      Executive Vice President and
                                      Chief Financial Officer

 

gehen ...

Sofern da nicht bald was "Großes" hinterher kommt ...  

Bid Ask vorbörslich bei 0,20-0,31. Die Mitte wären 0,25 oder 0,26 ;-)  

gehen? Soetwas verheisst meist nix gutes, da das ewige Personalgeschiebe nur Unruhe in den Laden bringt.
Ich denke auch, heute geht's weiter runter. Diese news sind leider mal wieder sauschlecht für Caly (nur meine bescheidene Meinung).

Grüße, ZN  

Mr. Gale commented, "Mr. Gwin's experience at OraSure in financial and operational management will be particularly valuable to the future growth of Calypte...."